423 related articles for article (PubMed ID: 9748598)
1. Secondary leukemias induced by topoisomerase-targeted drugs.
Felix CA
Biochim Biophys Acta; 1998 Oct; 1400(1-3):233-55. PubMed ID: 9748598
[TBL] [Abstract][Full Text] [Related]
2. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites.
Broeker PL; Super HG; Thirman MJ; Pomykala H; Yonebayashi Y; Tanabe S; Zeleznik-Le N; Rowley JD
Blood; 1996 Mar; 87(5):1912-22. PubMed ID: 8634439
[TBL] [Abstract][Full Text] [Related]
3. Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.
Mathew S; Head D; Rubnitz JE; Raimondi SC
Genes Chromosomes Cancer; 2000 Jun; 28(2):227-32. PubMed ID: 10825008
[TBL] [Abstract][Full Text] [Related]
4. Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides.
Langer T; Metzler M; Reinhardt D; Viehmann S; Borkhardt A; Reichel M; Stanulla M; Schrappe M; Creutzig U; Ritter J; Leis T; Jacobs U; Harbott J; Beck JD; Rascher W; Repp R
Genes Chromosomes Cancer; 2003 Apr; 36(4):393-401. PubMed ID: 12619163
[TBL] [Abstract][Full Text] [Related]
5. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
Felix CA; Hosler MR; Winick NJ; Masterson M; Wilson AE; Lange BJ
Blood; 1995 Jun; 85(11):3250-6. PubMed ID: 7756657
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint.
Archimbaud E; Charrin C; Magaud JP; Campos L; Thomas X; Fière D; Rimokh R
Leukemia; 1998 Jan; 12(1):25-33. PubMed ID: 9436917
[TBL] [Abstract][Full Text] [Related]
7. All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders.
Rowley JD; Reshmi S; Sobulo O; Musvee T; Anastasi J; Raimondi S; Schneider NR; Barredo JC; Cantu ES; Schlegelberger B; Behm F; Doggett NA; Borrow J; Zeleznik-Le N
Blood; 1997 Jul; 90(2):535-41. PubMed ID: 9226152
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11).
Domer PH; Head DR; Renganathan N; Raimondi SC; Yang E; Atlas M
Leukemia; 1995 Aug; 9(8):1305-12. PubMed ID: 7643617
[TBL] [Abstract][Full Text] [Related]
9. An in vivo topoisomerase II cleavage site and a DNase I hypersensitive site colocalize near exon 9 in the MLL breakpoint cluster region.
Strissel PL; Strick R; Rowley JD; Zeleznik-Le NJ
Blood; 1998 Nov; 92(10):3793-803. PubMed ID: 9808573
[TBL] [Abstract][Full Text] [Related]
10. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.
Lovett BD; Lo Nigro L; Rappaport EF; Blair IA; Osheroff N; Zheng N; Megonigal MD; Williams WR; Nowell PC; Felix CA
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9802-7. PubMed ID: 11493704
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the MLL breakpoint cluster region (BCR).
Echlin-Bell DR; Smith LL; Li L; Strissel PL; Strick R; Gupta V; Banerjee J; Larson R; Relling MV; Raimondi SC; Hayashi Y; Taki T; Zeleznik-Le N; Rowley JD
Hum Genet; 2003 Jul; 113(1):80-91. PubMed ID: 12665971
[TBL] [Abstract][Full Text] [Related]
12. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks.
Smith MA; Rubinstein L; Ungerleider RS
Med Pediatr Oncol; 1994; 23(2):86-98. PubMed ID: 8202047
[TBL] [Abstract][Full Text] [Related]
13. Identification of complex genomic breakpoint junctions in the t(9;11) MLL-AF9 fusion gene in acute leukemia.
Super HG; Strissel PL; Sobulo OM; Burian D; Reshmi SC; Roe B; Zeleznik-Le NJ; Diaz MO; Rowley JD
Genes Chromosomes Cancer; 1997 Oct; 20(2):185-95. PubMed ID: 9331569
[TBL] [Abstract][Full Text] [Related]
14. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.
Lovett BD; Strumberg D; Blair IA; Pang S; Burden DA; Megonigal MD; Rappaport EF; Rebbeck TR; Osheroff N; Pommier YG; Felix CA
Biochemistry; 2001 Feb; 40(5):1159-70. PubMed ID: 11170441
[TBL] [Abstract][Full Text] [Related]
15. Leukemias related to treatment with DNA topoisomerase II inhibitors.
Felix CA
Med Pediatr Oncol; 2001 May; 36(5):525-35. PubMed ID: 11340607
[TBL] [Abstract][Full Text] [Related]
16. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.
Andersen MK; Christiansen DH; Jensen BA; Ernst P; Hauge G; Pedersen-Bjergaard J
Br J Haematol; 2001 Sep; 114(3):539-43. PubMed ID: 11552977
[TBL] [Abstract][Full Text] [Related]
17. Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors.
Megonigal MD; Cheung NK; Rappaport EF; Nowell PC; Wilson RB; Jones DH; Addya K; Leonard DG; Kushner BH; Williams TM; Lange BJ; Felix CA
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2814-9. PubMed ID: 10706619
[TBL] [Abstract][Full Text] [Related]
18. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site.
Slater DJ; Hilgenfeld E; Rappaport EF; Shah N; Meek RG; Williams WR; Lovett BD; Osheroff N; Autar RS; Ried T; Felix CA
Oncogene; 2002 Jul; 21(30):4706-14. PubMed ID: 12096348
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing.
Whitmarsh RJ; Saginario C; Zhuo Y; Hilgenfeld E; Rappaport EF; Megonigal MD; Carroll M; Liu M; Osheroff N; Cheung NK; Slater DJ; Ried T; Knutsen T; Blair IA; Felix CA
Oncogene; 2003 Nov; 22(52):8448-59. PubMed ID: 14627986
[TBL] [Abstract][Full Text] [Related]
20. Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors.
Aplan PD; Chervinsky DS; Stanulla M; Burhans WC
Blood; 1996 Apr; 87(7):2649-58. PubMed ID: 8639880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
